Identifying the molecular mechanisms of synergistic and antagonistic drug-drug interactions in combination chemotherapies

确定联合化疗中协同和拮抗药物相互作用的分子机制

• 批准号: nhmrc : 1072965
• 负责人: Dr Adam Palmer
• 金额: $ 27.52万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/identifying-molecular-mechanisms-combination-chemotherapies/455538
• 关键词: Identifying; molecular; mechanisms; synergistic; antagonistic

Drug combinations in chemotherapy hold promise for more effective treatments and for overcoming drug resistance, but the search for effective combinations is challenging. The combination therapy R-CHOP is often curative for Diffuse Large B-cell Lymphoma (DLBCL). Both cellular drug interactions and evolutionary drug interactions will be quantified in DLBCL cells, to understand the defining features of effective combinations and guide the future rational design of combinations.

化疗中的药物组合有望更有效地治疗和克服耐药性，但寻找有效的组合是具有挑战性的。R-CHOP联合治疗弥漫性大b细胞淋巴瘤（DLBCL）常能治愈。细胞药物相互作用和进化药物相互作用将在DLBCL细胞中进行量化，以了解有效组合的定义特征，并指导未来合理设计组合。